NM_000287.4:c.210G>A

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_000287.4(PEX6):​c.210G>A​(p.Gly70Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0114 in 1,494,934 control chromosomes in the GnomAD database, including 124 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0064 ( 4 hom., cov: 33)
Exomes 𝑓: 0.012 ( 120 hom. )

Consequence

PEX6
NM_000287.4 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: -0.167
Variant links:
Genes affected
PEX6 (HGNC:8859): (peroxisomal biogenesis factor 6) This gene encodes a member of the AAA (ATPases associated with diverse cellular activities) family of ATPases. This member is a predominantly cytoplasmic protein, which plays a direct role in peroxisomal protein import and is required for PTS1 (peroxisomal targeting signal 1, a C-terminal tripeptide of the sequence ser-lys-leu) receptor activity. Mutations in this gene cause peroxisome biogenesis disorders of complementation group 4 and complementation group 6. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.5).
BP6
Variant 6-42978941-C-T is Benign according to our data. Variant chr6-42978941-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 92783.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-42978941-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.167 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00645 (981/152204) while in subpopulation NFE AF= 0.0118 (805/67980). AF 95% confidence interval is 0.0112. There are 4 homozygotes in gnomad4. There are 435 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 4 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PEX6NM_000287.4 linkc.210G>A p.Gly70Gly synonymous_variant Exon 1 of 17 ENST00000304611.13 NP_000278.3 Q13608-1A0A024RD09

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PEX6ENST00000304611.13 linkc.210G>A p.Gly70Gly synonymous_variant Exon 1 of 17 1 NM_000287.4 ENSP00000303511.8 Q13608-1
PEX6ENST00000244546.4 linkc.210G>A p.Gly70Gly synonymous_variant Exon 1 of 15 1 ENSP00000244546.4 Q13608-2

Frequencies

GnomAD3 genomes
AF:
0.00645
AC:
981
AN:
152096
Hom.:
4
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00203
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00216
Gnomad ASJ
AF:
0.00260
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00368
Gnomad MID
AF:
0.00318
Gnomad NFE
AF:
0.0118
Gnomad OTH
AF:
0.00478
GnomAD3 exomes
AF:
0.00615
AC:
575
AN:
93436
Hom.:
5
AF XY:
0.00593
AC XY:
313
AN XY:
52798
show subpopulations
Gnomad AFR exome
AF:
0.00482
Gnomad AMR exome
AF:
0.00266
Gnomad ASJ exome
AF:
0.00326
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000884
Gnomad FIN exome
AF:
0.00492
Gnomad NFE exome
AF:
0.0127
Gnomad OTH exome
AF:
0.00498
GnomAD4 exome
AF:
0.0120
AC:
16096
AN:
1342730
Hom.:
120
Cov.:
35
AF XY:
0.0116
AC XY:
7652
AN XY:
662302
show subpopulations
Gnomad4 AFR exome
AF:
0.00232
Gnomad4 AMR exome
AF:
0.00279
Gnomad4 ASJ exome
AF:
0.00389
Gnomad4 EAS exome
AF:
0.0000323
Gnomad4 SAS exome
AF:
0.000709
Gnomad4 FIN exome
AF:
0.00518
Gnomad4 NFE exome
AF:
0.0142
Gnomad4 OTH exome
AF:
0.0103
GnomAD4 genome
AF:
0.00645
AC:
981
AN:
152204
Hom.:
4
Cov.:
33
AF XY:
0.00585
AC XY:
435
AN XY:
74422
show subpopulations
Gnomad4 AFR
AF:
0.00202
Gnomad4 AMR
AF:
0.00216
Gnomad4 ASJ
AF:
0.00260
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00368
Gnomad4 NFE
AF:
0.0118
Gnomad4 OTH
AF:
0.00473
Alfa
AF:
0.00836
Hom.:
7
Bravo
AF:
0.00647

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:6
Apr 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

PEX6: BP4, BP7, BS1, BS2 -

Dec 16, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Feb 15, 2019
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 12, 2019
GeneDx
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 12, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

not specified Benign:2
Apr 27, 2018
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: PEX6 c.210G>A alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0064 in 122756 control chromosomes in the gnomAD database, including 5 homozygotes. The observed variant frequency is approximately 3.28 fold of the estimated maximal expected allele frequency for a pathogenic variant in PEX6 causing Zellweger Syndrome phenotype (0.0019), strongly suggesting that the variant is benign. The variant, c.210G>A, has been reported in the literature in individuals affected with Zellweger Syndrome (Ebberink_2010, Yik_2009) but were classified as neutral. These report(s) do not provide unequivocal conclusions about association of the variant with Zellweger Syndrome . To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as benign. Based on the evidence outlined above, the variant was classified as benign. -

Jun 19, 2016
Eurofins Ntd Llc (ga)
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

PEX6-related disorder Benign:1
Nov 14, 2019
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Peroxisome biogenesis disorder 4A (Zellweger);C3553937:Peroxisome biogenesis disorder 4B;C4225267:Heimler syndrome 2 Benign:1
Aug 04, 2021
Fulgent Genetics, Fulgent Genetics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Peroxisome biogenesis disorder 4A (Zellweger) Benign:1
Apr 27, 2017
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. -

Zellweger spectrum disorders Benign:1
Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Peroxisome biogenesis disorder Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.50
CADD
Benign
12
DANN
Benign
0.96

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.12
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs398123304; hg19: chr6-42946679; API